PRESS RELEASES

Date Title and Summary View
Aug 8, 2019
Summary ToggleZafgen Reports Second Quarter 2019 Operating and Financial Results
Agreement reached with U.S. FDA on in vivo animal study design and protocol to translate work from novel in vitro assays and establish relevant safety margins Topline data from the in vivo study expected by the end of 2019 PATH for PWS study over-enrolled with continued strong support from
Summary ToggleZafgen Reports Second Quarter 2019 Operating and Financial Results
Aug 6, 2019
Summary ToggleZafgen to Present at the Wedbush PacGrow Healthcare Conference
BOSTON , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey Hatfield
Summary ToggleZafgen to Present at the Wedbush PacGrow Healthcare Conference
Jul 24, 2019
Summary ToggleZafgen Announces Agreement with U.S. Food and Drug Administration on New Nonclinical Study Design for ZGN-1061
Alignment reached on in vivo animal study design and protocol to translate work from novel in vitro assays and establish relevant safety margins Topline data from the in vivo study expected by the end of 2019 Company has implemented measures to ensure the effective use of capital and extend cash
Summary ToggleZafgen Announces Agreement with U.S. Food and Drug Administration on New Nonclinical Study Design for ZGN-1061
Jun 13, 2019
Summary ToggleZafgen to Present at the JMP Securities Life Sciences Conference
BOSTON , June 13, 2019 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey Hatfield
Summary ToggleZafgen to Present at the JMP Securities Life Sciences Conference
Jun 10, 2019
Summary ToggleZafgen Presented Full Results of Phase 2 Clinical Trial for ZGN-1061 at the American Diabetes Association's 79th Scientific Sessions
Delivered comprehensive oral presentation on both cohorts of the clinical trial, including previously announced results for second cohort evaluating doses up to 1.8 mg Company also presented data demonstrating that treatment with ZGN-1061 improves measures of insulin sensitivity and beta-cell
Summary ToggleZafgen Presented Full Results of Phase 2 Clinical Trial for ZGN-1061 at the American Diabetes Association's 79th Scientific Sessions
May 30, 2019
Summary ToggleZafgen Announces Regulatory Update on ZGN-1061
Received FDA Type A meeting minutes related to previously announced clinical hold FDA acknowledged newly developed in vitro assays of human plasma coagulation and tissue factor expression qualitatively differentiate ZGN-1061 Company is working with FDA to translate in vitro data and confirm
Summary ToggleZafgen Announces Regulatory Update on ZGN-1061
May 9, 2019
Summary ToggleZafgen Reports First Quarter 2019 Operating and Financial Results
Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061              Company is currently in the formal regulatory process related to the clinical hold for ZGN-1061; Update still anticipated in Q2 2019 PATH for PWS study continues enrollment with strong support
Summary ToggleZafgen Reports First Quarter 2019 Operating and Financial Results
May 2, 2019
Summary ToggleZafgen to Announce First Quarter 2019 Financial Results
BOSTON , May 02, 2019 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will announce
Summary ToggleZafgen to Announce First Quarter 2019 Financial Results
Apr 4, 2019
Summary ToggleZafgen, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON , April 04, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) (the “Company”) a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, today announced that on
Summary ToggleZafgen, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mar 13, 2019
Summary ToggleZafgen to Present at the 31st Annual ROTH Conference
BOSTON , March 13, 2019 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey Hatfield
Summary ToggleZafgen to Present at the 31st Annual ROTH Conference